Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report
Open Access
- 1 August 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Research Reports in Clinical Cardiology
- Vol. ume 12, 33-39
- https://doi.org/10.2147/rrcc.s316980
Abstract
Dasatinib was identified to be associated with pulmonary arterial hypertension, also called dasatinib-induced pulmonary arterial hypertension. There was still little data on clinical characteristics of this rare but severe complication during hematological therapy in China. A 40-year-old female with worsening dyspnoea was diagnosed with severe pulmonary arterial hypertension and progressive right heart failure, and stabilized by standardized comprehensive management, including replacement of other tyrosine kinase inhibitor, administration of pulmonary vasodilators according to the right-heart catheterization-based risk stratification and traditional anti-heart failure drug therapy. Our case suggests that dasatinib-induced pulmonary arterial hypertension may be partially reversible, with a relatively good prognosis under formal target therapy of pulmonary arterial hypertension, providing new insight into its treatment algorithm.Keywords
This publication has 11 references indexed in Scilit:
- Dasatinib‐induced pulmonary arterial hypertensionBritish Journal of Clinical Pharmacology, 2018
- Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based studyEuropean Respiratory Journal, 2017
- Tyrosine Kinase Inhibitors in Pulmonary Vascular DiseaseJACC: Basic To Translational Science, 2016
- Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertensionJCI Insight, 2016
- Clinical features of pulmonary arterial hypertension in patients receiving dasatinibAmerican Journal of Hematology, 2015
- Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid LeukemiaCancer Research and Treatment, 2014
- [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].Chinese Journal of Hematology, 2014
- Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?Critical Reviews in Oncology/Hematology, 2014
- Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patientBone Marrow Transplantation, 2008
- Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib FailureJournal of Clinical Oncology, 2007